PGE 2 synthesis and signaling in malignant transformation and progression of human hepatocellular carcinoma

Zang, Shengbing; Ma, Xiaojie; Wu, Yanbin; Liu, Wenwen; Cheng, Haili; Li, Jiasi; Liu, Jingfeng; Huang, Aimin

doi:10.1016/j.humpath.2017.02.018

Cited by 24 publications

(21 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, Akt pathway activation promoted by EP4 receptor results in the activation of mTORC1 [109]. Several other studies have shown that EP2 and EP4 induce the activation of multiple signaling cascades that are associated with squamous cell carcinoma (SCC) [110,111]; human hepatocellular carcinoma (HCC) [112]; glioma [113]; prostate [114], bladder [115], endometrial [116], and breast cancer [117] cell growth.…”

Section: Molecular Mechanisms Linking Pge2 and Tumor Progressionmentioning

confidence: 99%

Prostaglandin E2 and Cancer: Insight into Tumor Progression and Immunity

Finetti

Travelli

Ercoli

et al. 2020

Biology

179

146

View full text Add to dashboard Cite

The involvement of inflammation in cancer progression has been the subject of research for many years. Inflammatory milieu and immune response are associated with cancer progression and recurrence. In different types of tumors, growth and metastatic phenotype characterized by the epithelial mesenchymal transition (EMT) process, stemness, and angiogenesis, are increasingly associated with intrinsic or extrinsic inflammation. Among the inflammatory mediators, prostaglandin E2 (PGE2) supports epithelial tumor aggressiveness by several mechanisms, including growth promotion, escape from apoptosis, transactivation of tyrosine kinase growth factor receptors, and induction of angiogenesis. Moreover, PGE2 is an important player in the tumor microenvironment, where it suppresses antitumor immunity and regulates tumor immune evasion, leading to increased tumoral progression. In this review, we describe the current knowledge on the pro-tumoral activity of PGE2 focusing on its role in cancer progression and in the regulation of the tumor microenvironment.

show abstract

Section: Molecular Mechanisms Linking Pge2 and Tumor Progressionmentioning

confidence: 99%

Prostaglandin E2 and Cancer: Insight into Tumor Progression and Immunity

Finetti

Travelli

Ercoli

et al. 2020

Biology

179

146

View full text Add to dashboard Cite

show abstract

“…Furthermore, this study suggested that a decrease in prostaglandin E (PGE)-2 might be associated with such anti-cancer effects in addition to immunity-related host resistance [ 30 ]. The PGE-2 system is recognized widely as stimulator of carcinogenesis, cancer cell proliferation and invasion and as an inhibitor of apoptosis in various types of cancers [ 31 , 32 , 33 ]. Furthermore, PGE2 is an important modulator for the activities of immune cells, including macrophages, dendritic cells and natural killer cells [ 34 , 35 , 36 ].…”

Section: Anti-cancer Effects Of Royal Jelly and Its Componentsmentioning

confidence: 99%

Anti-Cancer and Protective Effects of Royal Jelly for Therapy-Induced Toxicities in Malignancies

Miyata

Sakai

2018

IJMS

View full text Add to dashboard Cite

Royal jelly (RJ) is a glandular secretion produced by worker honeybees and is a special food for the queen honeybee. It results in a significant prolongation of the lifespan of the queen honeybee compared with the worker honeybees through anti-inflammatory, anti-oxidant and anti-microbial activities. Consequently, RJ is used as cosmetic and dietary supplement throughout the world. In addition, in vitro studies and animal experiments have demonstrated that RJ inhibits cell proliferation and stimulates apoptosis in various types of malignant cells and affects the production of various chemokines, anti-oxidants and growth factors and the expression of cancer-related molecules in patients with malignancies, especially in patients treated with anti-cancer agents. Therefore, RJ is thought to exert anti-cancer effects on tumor growth and exhibit protective functions against drug-induced toxicities. RJ has also been demonstrated to be useful for suppression of adverse events, the maintenance of the quality of life during treatment and the improvement of prognosis in animal models and patients with malignancies. To understand the mechanisms of the beneficial effects of RJ, knowledge of the changes induced at the molecular level by RJ with respect to cell survival, inflammation, oxidative stress and other cancer-related factors is essential. In addition, the effects of combination therapies of RJ and other anti-cancer agents or natural compounds are important to determine the future direction of RJ-based treatment strategies. Therefore, in this review, we have covered the following five issues: (1) the anti-cancer effects of RJ and its main component, 10-hydroxy-2-decenoic acid; (2) the protective effects of RJ against anti-cancer agent-induced toxicities; (3) the molecular mechanisms of such beneficial effects of RJ; (4) the safety and toxicity of RJ; and (5) the future directions of RJ-based treatment strategies, with a discussion on the limitations of the study of the biological activities of RJ.

show abstract

“…The function of the EP2 receptor. Numerous studies have demonstrated that EP2 is abnormally expressed in cancer, including colon, prostate, liver and breast cancer (5,(40)(41)(42)(43) (Fig. 4).…”

Section: Regulating the Function Of The Ep2 Receptor In Cancermentioning

confidence: 99%

Prostaglandin EP2 receptor: Novel therapeutic target for human cancers (Review)

Sun

2018

Int J Mol Med

View full text Add to dashboard Cite

Prostaglandin E2 (PGE2) receptor 2 subtype (EP2), which is a metabolite of arachidonic acid that binds with and regulates cellular responses to PGE2, is associated with numerous physiological and pathological events in a wide range of tissues. As a stimulatory G protein‑coupled receptor, PGE2‑induced EP2 activation can activate adenylate cyclase, leading to increased cytoplasmic cAMP levels and activation of protein kinase A. The EP2 receptor can also activate the glycogen synthase kinase 3β and β‑catenin pathways. The present study aimed to review the roles of the EP2 receptor in tumor development, including immunity, chronic inflammation, angiogenesis, metastasis and multidrug resistance. Furthermore, the involvement of the EP2 receptor signaling pathway in cancer was discussed. Understanding the role and mechanisms of action of the EP2 receptor, and its importance in targeted therapy, may help identify novel methods to improve management of numerous types of cancer.

show abstract

PGE 2 synthesis and signaling in malignant transformation and progression of human hepatocellular carcinoma

Cited by 24 publications

References 35 publications

Prostaglandin E2 and Cancer: Insight into Tumor Progression and Immunity

Prostaglandin E2 and Cancer: Insight into Tumor Progression and Immunity

Anti-Cancer and Protective Effects of Royal Jelly for Therapy-Induced Toxicities in Malignancies

Prostaglandin EP2 receptor: Novel therapeutic target for human cancers (Review)

Contact Info

Product

Resources

About